NAD Backs Some Kendamil Claims, Orders Changes to Others

Regulation
โดย GlobeNewswire·USGB·Read original
Summary · why it matters

In a challenge brought by Abbott Laboratories, the National Advertising Division determined that Kendal Nutricare Limited substantiated certain claims about the use of whole milk in its Kendamil infant formula, but recommended that the company modify or discontinue other claims regarding nutritional benefits, ingredients, and heritage. NAD found that Kendal's whole milk ingredient claims were supported, but it recommended discontinuing the claim that competing formulas lose "natural milk fats and important nutrients" because it implied nutritional inferiority without evidence. The division also recommended discontinuing claims that Kendamil's whole milk keeps natural fats closer to breast milk and that its HMO blend supports immune health, as the evidence did not fit those product-specific claims. Additionally, NAD advised Kendal to modify or discontinue heritage claims like "Est. 1962" and "60 years of experience" to clarify they refer to the manufacturing facility, not the brand's age. Kendal stated it will comply with NAD's recommendations.

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks
Abbott Laboratories
ABT
▲ PositiveRegulationrelevance

Abbott brought the NAD challenge and won recommendations that Kendal discontinue or modify several comparative claims about its formula.

Off-coverage companies 1

Kendal Nutricare LimitedPrivate▼ Negative
Regulationrelevance

NAD recommended Kendal modify or discontinue multiple claims about nutritional benefits, ingredients, and heritage, though some whole-milk claims were substantiated.

© 2026 MarketDXNews